Koers OncoSec Medical Inc Nasdaq
Aandelen
US68234L2079
Biotechnologie & Medisch Onderzoek
Omzet 2021 | - | Omzet 2022 | - | Marktkapitalisatie | 28,35 mln. 26,57 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -45 mln. -42,18 mln. | Nettowinst (verlies) 2022 | -34 mln. -31,87 mln. | EV/omzet 2021 | - |
Nettoliquiditeiten 2021 | 33,63 mln. 31,52 mln. | Nettoliquiditeiten 2022 | 1,12 mln. 1,05 mln. | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-1,59
x | K/w-verhouding 2022 |
-0,83
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 84,57% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Canton
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-14 |
Sandra Aung
PRN | Corporate Officer/Principal | - | 12-10-20 |
Bridget O'Keeffe
PRN | Corporate Officer/Principal | - | 18-02-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,17% | 42,19 mld. | |
+10,92% | 42,24 mld. | |
+44,30% | 40,15 mld. | |
-6,20% | 28,31 mld. | |
+5,23% | 24,63 mld. | |
-24,79% | 18,2 mld. | |
+26,69% | 12,01 mld. | |
-3,13% | 11,76 mld. | |
+6,57% | 10,4 mld. |